Patient characteristics
| . | n (%) . |
|---|---|
| Total number of MGUS patients | 290 (100) |
| Age at time of COVID-19 diagnosis, years | 73 (23-99)∗ |
| Female sex | 112 (39) |
| Anti-CD38 therapy within 6 months of COVID-19 diagnosis | 3/289 (1) |
| Monoclonal gammopathy of renal significance | 2/289 (0.7) |
| Type 3 cryoglobulinemia | 1/289 (0.3) |
| Immunoparesis within 3 months of COVID-19 diagnosis | 54/101 (53) |
| Severity of COVID-19 infection | |
| Asymptomatic/Mild | 167 (58) |
| Moderate | 52 (18) |
| Severe | 71 (24) |
| Hospitalization needed during COVID-19 infection | 97/289 (34) |
| ICU admission during COVID-19 infection | 22/289 (8) |
| Mechanical ventilation required | 9/289 (3) |
| VTE during COVID-19 infection | 12/289 (4) |
| Number of COVID infections | |
| 1 | 277 (96) |
| 2 | 13 (4) |
| Deceased at follow-up | 30 (10) |
| COVID-19–associated deaths | 16 (6) |
| Cardiovascular complications | 3 (1) |
| Non-COVID-19 infection | 3 (1) |
| ESRD | 2 (0.7) |
| Fall | 2 (0.7) |
| Bowel perforation | 1 (0.3) |
| COPD exacerbation | 1 (0.3) |
| Dementia | 1 (0.3) |
| Unclear | 1 (0.3) |
| . | n (%) . |
|---|---|
| Total number of MGUS patients | 290 (100) |
| Age at time of COVID-19 diagnosis, years | 73 (23-99)∗ |
| Female sex | 112 (39) |
| Anti-CD38 therapy within 6 months of COVID-19 diagnosis | 3/289 (1) |
| Monoclonal gammopathy of renal significance | 2/289 (0.7) |
| Type 3 cryoglobulinemia | 1/289 (0.3) |
| Immunoparesis within 3 months of COVID-19 diagnosis | 54/101 (53) |
| Severity of COVID-19 infection | |
| Asymptomatic/Mild | 167 (58) |
| Moderate | 52 (18) |
| Severe | 71 (24) |
| Hospitalization needed during COVID-19 infection | 97/289 (34) |
| ICU admission during COVID-19 infection | 22/289 (8) |
| Mechanical ventilation required | 9/289 (3) |
| VTE during COVID-19 infection | 12/289 (4) |
| Number of COVID infections | |
| 1 | 277 (96) |
| 2 | 13 (4) |
| Deceased at follow-up | 30 (10) |
| COVID-19–associated deaths | 16 (6) |
| Cardiovascular complications | 3 (1) |
| Non-COVID-19 infection | 3 (1) |
| ESRD | 2 (0.7) |
| Fall | 2 (0.7) |
| Bowel perforation | 1 (0.3) |
| COPD exacerbation | 1 (0.3) |
| Dementia | 1 (0.3) |
| Unclear | 1 (0.3) |
COPD, chronic obstructive pulmonary disease: ESRD, end-stage renal disease. ICU, intensive care unit; MGUS, monoclonal gammopathy of undetermined significance; VTE, venous thromboembolism.
Median (range).